Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2025-09-11T20:04:31.372988Z
Market Cap
9.43M

Momentum Score

…

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.04
Low
0.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
48.54M
Revenue Per Share
1.72
Gross Profit TTM
17.70M
Debt / Equity
-3.18
ROE
-1375.33%
Net Debt
61.29M
ROCE
-107.98%
Diluted EPS TTM
-1.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -38.60M -46.88M -21.10M -20.70M -11.65M
Minority interest - - 0.10M -0.94M -0.76M
Net income -38.70M -46.85M -21.38M -20.86M -11.34M
Selling general administrative 29.21M 44.79M 37.66M 23.16M 18.61M
Selling and marketing expenses 9.92M 9.86M 7.58M 9.25M 7.47M
Gross profit 19.76M 28.16M 42.00M 22.77M 20.54M
Reconciled depreciation 10.38M 21.29M 15.13M 6.58M 5.17M
Ebit -36.52M -44.82M -15.96M -19.34M -9.68M
Ebitda -26.00M -23.53M -0.82M -12.74M -4.50M
Depreciation and amortization 10.52M 21.29M 15.13M 6.59M 5.17M
Non operating income net other - - - 0.00M 0.00M
Operating income -36.52M -44.82M -15.96M -19.34M -10.61M
Other operating expenses 83.99M 234.74M 144.34M 68.12M 50.19M
Interest expense 3.57M 0.85M 1.04M 2.03M 1.07M
Tax provision 0.11M -0.02M 0.28M 0.16M -0.31M
Interest income 0.00M 0.00M 0.01M 0.02M 0.03M
Net interest income -3.43M -0.85M -1.03M -2.01M -1.04M
Extraordinary items - - - 0.00M 0.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense 0.11M -0.02M 0.28M 0.16M -0.31M
Total revenue 47.47M 189.92M 128.38M 48.78M 40.48M
Total operating expenses 56.28M 72.98M 57.96M 42.11M 30.25M
Cost of revenue 27.71M 161.76M 86.38M 26.00M 19.94M
Total other income expense net -2.08M -2.06M -5.14M -1.36M -0.90M
Discontinued operations 6.86M 6.86M 6.86M 6.86M 0.00M
Net income from continuing ops -38.70M -46.85M -21.38M -20.86M -11.34M
Net income applicable to common shares - -46.85M -21.38M -20.86M -11.34M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 77.22M 92.81M 90.69M 150.13M 117.51M
Intangible assets 6.85M 7.40M 9.19M 12.41M 14.14M
Other current assets 2.31M 5.51M 5.45M 8.29M 5.85M
Total liab 96.82M 85.40M 63.19M 84.35M 58.59M
Total stockholder equity -25.30M 7.41M 27.31M 65.68M 59.86M
Deferred long term liab - - - - 0.00M
Other current liab 8.99M 10.14M 19.65M 18.02M 13.12M
Common stock 3.48M 3.31M 2.71M 2.65M 2.38M
Capital stock 3.48M 3.31M 2.71M 2.65M 2.38M
Retained earnings -177.36M -141.26M -109.30M -62.89M -40.62M
Other liab - - 8.11M 9.16M 9.94M
Good will - - - - 0.00M
Other assets - - 2.97M 1.97M 1.95M
Cash 19.11M 32.01M 13.38M 43.16M 36.59M
Total current liabilities 43.40M 24.66M 39.50M 57.12M 29.00M
Current deferred revenue 0.69M 1.26M 1.37M 1.34M -
Net debt 61.29M 28.11M 9.43M -19.06M -9.62M
Short term debt 28.08M 6.95M 7.22M 6.02M 7.32M
Short long term debt 25.88M 4.63M 3.81M 2.49M 3.69M
Short long term debt total 80.41M 60.12M 22.81M 24.10M 26.97M
Other stockholder equity 148.43M - 27.50M 58.92M 106.48M
Property plant equipment - - 27.05M 38.71M 33.31M
Total current assets 44.06M 59.83M 51.48M 97.05M 68.11M
Long term investments 2.78M - - - 0.00M
Net tangible assets - 0.01M 18.12M 53.27M 45.72M
Short term investments - - - - 0.00M
Net receivables 20.16M 16.55M 24.34M 29.20M 19.36M
Long term debt 39.88M 40.05M - 0.40M 1.58M
Inventory 2.47M 1.82M 3.87M 11.40M 1.81M
Accounts payable 5.63M 6.32M 11.25M 31.74M 8.55M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income 0.15M 145.37M 133.90M 125.92M 98.10M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - 2.65M 2.38M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other 3.43M 3.42M 2.97M 1.97M 1.95M
Deferred long term asset charges - - - - 0.00M
Non current assets total 33.16M 32.98M 39.22M 53.08M 49.40M
Capital lease obligations 14.58M 15.44M 19.00M 21.20M 21.70M
Long term debt total - - - - 19.65M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.73M -5.36M -16.15M 14.18M -8.69M
Change to liabilities -4.93M -20.48M 24.00M 3.12M 0.14M
Total cashflows from investing activities - -5.36M -16.15M 14.18M -8.69M
Net borrowings - -2.94M -7.34M -14.40M 0.34M
Total cash from financing activities 46.32M -3.20M 14.84M 25.47M 19.34M
Change to operating activities - 3.46M 6.50M 2.13M 0.64M
Net income -31.72M -46.88M -21.10M -20.70M -11.65M
Change in cash 18.13M -30.34M 7.06M 31.87M 6.07M
Begin period cash flow 17.82M 48.16M 41.09M 9.22M 3.16M
End period cash flow 35.95M 17.82M 48.16M 41.09M 9.22M
Total cash from operating activities -26.49M -21.74M 8.46M -7.78M -4.58M
Issuance of capital stock 12.14M 0.00M 22.43M 41.90M 20.07M
Depreciation 10.38M 21.29M 15.13M 6.58M 5.17M
Other cashflows from investing activities - 0.17M 0.40M 0.45M 3.08M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory 2.05M 5.74M -9.60M -0.46M -0.57M
Change to account receivables - 4.19M -16.34M -5.69M -3.91M
Sale purchase of stock - - - 41.90M 20.07M
Other cashflows from financing activities 38.49M 1.50M 0.19M -1.31M 2.56M
Change to netincome - 10.33M 10.16M 7.40M 5.29M
Capital expenditures 2.09M 5.70M 16.55M 7.58M 11.77M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital -6.15M -7.09M 4.56M -0.90M -3.70M
Stock based compensation -0.02M 8.04M 5.66M 6.42M 5.52M
Other non cash items 1.11M -0.01M 0.48M -0.38M 0.08M
Free cash flow -28.58M -27.44M -8.09M -15.35M -16.35M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Centogene B V

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Am Strande 7, Rostock, Germany, 18055

49 381 80113 500

384

Name Title Year Born
Dr. Andrin Oswald M.D., Ph.D. Advisor 1972
Ms. Kim Stratton CEO & Member of Management Board 1962
Mr. Jose Miguel Coego Rios Chief Financial Officer NA
Dr. Patrice P. Denefle Ph.D. Chief Scientific Officer 1960
Mr. Florian Vogel Ph.D. Chief Process Officer 1981
Dr. Peter Bauer M.D. Chief Medical & Genomic Officer 1969
Ms. Bettina Goerner Chief Data Officer 1984
Mr. Lennart M. Streibel Director of Corp. Projects NA
Mr. Jose Miguel Coego Rios CFO, Legal & IT and Member of Management Board NA
Dr. Peter Bauer M.D. Chief Medical & Genomic Officer and Member of Management Board 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…